The correlation between pre-treatment CEA levels and the EGFR mutation status in advanced lung adenocarcinoma

Basit Öğe Kaydı
dc.contributor.authorUysal, Mukremin
dc.contributor.authorBeypinar, Ismail
dc.contributor.authorAraz, Murat
dc.date.accessioned2026-01-24T12:26:38Z
dc.date.available2026-01-24T12:26:38Z
dc.date.issued2024
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractBackground: The discovery of the epidermal growth factor receptor (EGFR) mutation, especially in adenocarcinoma, has led to a major change in the treatment of non-small-cell lung cancer (NSCLC). This study investigated the relationship between the EGFR mutation status and the carcinoembryonic antigen (CEA) levels at the time of diagnosis. Materials and Methods: A total of 102 patients with EGFR mutation and tested CEA levels were recruited for this study. Of the patients, 24 were EGFR mutants (23.5%), while 78 patients (76.5%) did not harbor any EGFR mutations. Results: The CEA levels did not differ across groups. Additionally, the CEA levels were analyzed between female and male patients separately due to EGFR mutations; no difference was observed. When the CEA levels were categorized as positive or negative based on different cut-off values, such as 5 and 10 ng/ml, no statistical difference was found between groups. Conclusion: In this study, no relationship between EGFR mutation and pre-treatment CEA levels was observed. Despite positive trials having shown a predictive value of CEA levels for EGFR mutation, more clinical trials are needed to elucidate the racial, clinical, and pathological differences of the study populations. Most studies have been located in the Far East, but new trials in Caucasian, African, and Hispanic populations are still lacking.
dc.identifier.doi10.4103/jcrt.JCRT_1459_20
dc.identifier.endpage912
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issue3
dc.identifier.pmid38261436
dc.identifier.scopus2-s2.0-85197585199
dc.identifier.scopusqualityQ3
dc.identifier.startpage909
dc.identifier.urihttps://doi.org/10.4103/jcrt.JCRT_1459_20
dc.identifier.urihttps://hdl.handle.net/20.500.12868/4833
dc.identifier.volume20
dc.identifier.wosWOS:001316341200028
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWolters Kluwer Medknow Publications
dc.relation.ispartofJournal of Cancer Research and Therapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260121
dc.subjectCEA
dc.subjectEGFR mutation
dc.subjectlung adenocarcinoma
dc.subjectnon-small-cell lung cancer
dc.titleThe correlation between pre-treatment CEA levels and the EGFR mutation status in advanced lung adenocarcinoma
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu